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Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is
used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in cap-
tivity with good reproductive efﬁciencies and their sexual maturity is reached within 18 months of age
allowing for rapid expansion of colonies and early availability of sexually mature animals permitting
an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction
in material requirements leading to a reduction in development time and cost. Fewer animals are also
required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These
factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent
years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-
derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is
also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may
provide the optimal compromise and once the scientiﬁc rationale has been carefully considered and their
use justiﬁed, there are several advantages to using the marmoset as a model in nonclinical development
of pharmaceutical products.
 2010 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Before evaluation in human volunteer or patient clinical studies,
all investigational medicinal products (IMPs, e.g. pharmaceuticals
including biotechnology derived products, gene therapies and
vaccines) require evaluation in nonclinical toxicology and safety
studies, generally in a rodent and a non-rodent (‘second’) species;
(ICH-Topic-M3(R2), 2009). These nonclinical toxicology and safety
studies allow a risk assessment to be performed to act as a safe-
guard for human subjects. The use of a non-rodent species in addi-
tion to a rodent species aims at limiting the uncertainty in the
extrapolation process from animal toxicity and safety data to the
human situation. Dogs, and in speciﬁc circumstances minipigs,
are the more frequently used non-rodent species (ICH-Topic-
M3(R2), 2009). However, when it is scientiﬁcally justiﬁed that
these are inappropriate, regulatory authorities worldwide accept
the use of non-human primates. Non-human primates are also
used when they represent a well-established model of a compound
class or when they are the relevant species (especially for biotech-
nology-derived products) for detecting known side effects or upon
speciﬁc recommendations from regulatory authorities. ‘‘New
World monkeys’’ such as Callithrix jacchus (the commonmarmoset)Orsi).
-NC-ND license.and the larger ‘‘Old World monkeys’’ such as Macaca Fascicularis
(cynomolgus monkeys) and Macaca Mulatta (rhesus monkeys)
are typically used (Weatherall, 2006; SCHER, 2009). This paper
provides a general overview of the marmoset as model in nonclin-
ical development of pharmaceutical products taking into account
the recent regulatory changes in husbandry, new micro sampling
technologies, the requirements for reducing primate use alongside
the contrasting need for relevant species selection in biotechnol-
ogy derived product development.
2. Marmoset characteristics
2.1. Regulatory acceptance
Regulatory authorities worldwide recognize the use of marmo-
sets in nonclinical development and as they are one of the more
primitive, non-human primate species and the most phylogeneti-
cally distant from humans, their use requires less ethical justiﬁca-
tion than the larger ‘‘Old World monkeys’’ (Home–Ofﬁce, 2000).
2.2. Small body size
The marmoset is a relatively small animal, approximately the
size of an adult rat (up to 500 g; Table 1). Their small size has sev-
eral advantages during the early phases of IMP development, as
Table 1
Growth characteristics of the marmoset.
Characteristics Description
Weight (g)
Birth 20–35
Weaning 60–150
Adult 200–600
Length (cm)
Adult without tail Up to 20
Adult tail length Up to 35
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quantities can be rate limiting for studies. Since the amount of
material required is roughly proportional to the size of the animals
there are signiﬁcant savings, both in cost and time, in the use of
smaller species such as marmosets. The reduction in material
requirement has been estimated to be 10–15-fold when comparing
a 500 g marmoset to a 5–10 kg macaque (Weatherall, 2006;
Zuhlke and Weinbauer, 2003; Smith et al., 2001). Shorter synthesis
time offers the potential for earlier administration to human sub-
jects which in turn may lead to substantial cost savings (estimates
range from 12 to 18 months’ reduction in development time). The
reduction in the amount of material required for early develop-
ment studies may also have a corresponding beneﬁt in allowing
more time for large scale synthesis optimization, with further
opportunities for beneﬁt in time and costs later in development
(Smith et al., 2001). The marmoset also requires smaller cages than
those for larger non-human primates and manymethodologies and
technologies used for the rat can also be used for the marmoset
such as metabolic cages.
In the past, in certain circumstances, their small size was con-
sidered a potential hurdle as larger volumes of blood were needed
for pharmacokinetic and toxicokinetic investigations, resulting in
an increased number of animals required with a consequent in-
crease in material requirement and cost. Nowadays, the need for
large blood volumes has diminished with the availability of more
sensitive analytical techniques such as ‘‘dried spot detection’’,
newer clinical pathology techniques and enzyme linked immuno
assay (ELISA) kits (Pastori et al., 2010; Dunbar, 2006; Hu andWang,
2007; http://www.sfbr.org/SNPRC/detail.aspx?r=60, 2010).
2.3. Breeding and sexual development
The marmoset breeds well in captivity and nowadays nearly all
marmosets used are captive bred and have been for sometime (F 4/
5 generation), providing a more reproducible dataset (SCHER,
2009). The marmoset has a high reproductive efﬁciency, typically
producing twins twice a year with sexual maturity reached within
18 months of age (compared to approximately 4 years for ‘‘Old
World monkeys’’). This aspect is particularly important, as the is-
sue of toxicity studies conducted in non-rodent species where
the animals are not sexually mature has been of considerable con-
cern. The high reproductive efﬁciency also allows for the rapid
establishment of an in-house breeding colony, with easier avail-
ability of animals and more reliable results due to reduced stress
from transportation and colony alterations. A secondary beneﬁt
is a reduction in overall cost. Furthermore, the life cycle of the mar-
moset is physiologically faster (7–20 years) than that of the ‘‘Old
World monkeys’’ resulting in greater availability of aged animals,
an important aspect for studies involving aging and bone disease.
2.4. Other characteristics
Marmosets are born as naturally occurring chimeras, so
although the animals are genetically distinct, they share and aretolerant to each other cells (Niblack et al., 1977; Ross et al.,
2007). This natural chimerism enables the study of cell transfer
without initiating an alloresponse (Mansﬁeld et al., 2004).3. Marmoset management
The marmoset is an arboreal, diurnal species originating from
the South American forests and as such a suitable environment
and diet is required to reﬂect this natural habitat.3.1. Husbandry
3.1.1. European guidelines
The natural behavior of marmosets indicates that the captive
environment should have a degree of complexity and stimulation
(OJ-L-197-(vol-50), 2007) and due to their arboreal nature the vol-
ume of available space and the vertical height of the enclosure ap-
pear to be more important than ﬂoor area (Badihi et al., 2007).
The European guidelines for their housing recommend the
following:
 The marmosets should be housed in groups and during studies
in pairs.
 Cages should be constructed with a height of at least 1.5 m
(with the top of the cage at least 1.8 m from the ﬂoor) and a
minimum ﬂoor area of 0.55 m2 for a breeding pair and 2.0 m2
for family groups (OJ-L-197-(vol-50), 2007).
 Rich and complex environments, including opportunities for
climbing, foraging (e.g. via puzzle feeders high up in cages),
gnawing, swinging, and social play, as well as rest places should
be provided. The cages should be equipped with wooden bars
and hiding provisions and should take into account that mar-
mosets are used to an arboreal habitat. It is important to pro-
vide a certain degree of variability in orientation, diameter
and ﬁrmness to allow the animals to perform appropriate loco-
motor and jumping behaviors (Weatherall, 2006; OJ-L-197-
(vol-50), 2007) (Fig. 1 and Fig. 2).
 Marmosets frequently scent-mark their environment and the
total removal of familiar scent may cause behavioral problems.
Alternate cleaning and sanitation of the enclosure and the
enrichment devices retains some of the territorial scent-mark-
ing. Regular handling and human contact are beneﬁcial for
improving the animals’ habituation to monitoring and experi-
mental conditions and facilitate training to co-operate with
some procedures.
 Since the marmosets originate from tropical rain forests, they
should be kept at a relatively high temperature of 23–28 C with
a relative humidity of between 45 and 70%. A light and dark
cycle of 12 h is recommended. The lighting source should illu-
minate uniformly the holding room. However, within the ani-
mal enclosures, a shaded area should always be provided.
 Special consideration should be given to minimize exposure to
ultrasound and any sudden unexpected noise, within the hear-
ing range of marmosets (OJ-L-197-(vol-50), 2007).
3.1.2. Other guidelines and recommendations
The United States National Research Council’s ‘‘Guide for the
Care and Use of Laboratory Animals’’ integrates recently published
data, scientiﬁc principles and expert opinion to recommend prac-
tices for the humane care and use of animals in research, testing,
and teaching (National Research Council, 2010). The ‘‘Guide’’ is
an internationally accepted primary reference on animal care for
the scientiﬁc community and previous editions have served as
the basis for accreditation of institutions worldwide by the Associ-
Fig. 1. An example of a modern housing facility for marmosets. Each cage can be
divided in length and contains wooden hand-made enrichments and entertain-
ments. One side of each cage is removable creating larger cage for family groups.
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International (AAALAC).
The ‘‘Guide’’ recommends:
 Minimum space based on the needs of pair or group housed
marmosets; however the group composition should be critically
considered.
 Cages with a minimum height of at least 76.2 cm and a mini-
mum ﬂoor area of 0.20 m2 for a breeding pair. However this rec-
ommendation highlights that in light of the marmosets arboreal
nature, taller cages should be utilized, with species-speciﬁc
environmental and psychological enrichments (National
Research Council, 2010).
The marmosets’ climate tolerance, monogamy and preference
for living in small family groups make it comparatively straightfor-Fig. 2. Marmosets in a moward to provide housing and husbandry that meets the animals’
needs and promotes their well-being. This is a signiﬁcant advan-
tage over the larger non-human primates where it is considerably
more difﬁcult to provide laboratory housing, due not only to their
larger physical size, but also their greater natural troop, home
range sizes, and social characteristics, including complex domi-
nance relationships and aggressive tendencies (Baskerville, 1999).
This, coupled with the physical and microbiological health haz-
ards that the larger non-human primates pose to humans (as well
as climate requirements of cynomolgus monkeys) suggests that
husbandry of marmosets, is one of the major advantages in provid-
ing an acceptable quality of life for them as laboratory animals.
From an ethical perspective there are several beneﬁts in using mar-
mosets, as their characteristics facilitate the provision of a more
complex and enriched environments, being less destructive than
larger non-human primates. Their greater wellbeing from this
environment should also translate into more consistent and reli-
able results and over the last few decades extensive databases have
also been generated within companies, toxicology service provid-
ers and breeding establishments providing essential background
data to support this (Abbott, 2003; Smith et al., 2001).3.2. Food
Marmosets eat fresh fruit, bread loaf, eggs, nuts high protein in-
take. A commercial supplement is also available (e.g. ‘‘New World
monkey’’ prepared diet by Harlan Teklad). Biscuits and condensed
milk are also typically used as remuneration food (RTC S.p.A.;
internal procedures). The marmoset has a high requirement for
protein and since they are unable to synthesize vitamin D3 without
access to UV-B radiation, the diet must also be supplemented with
adequate levels of vitamin D3 (OJ-L-197-(vol-50), 2007). Continual
improvements in diet as well as husbandry and environmental
enrichments are helping to dramatically reduce the incidence of
the marmoset ‘wasting syndrome’ (Tucker, 1984) resulting in the
generation of more consistent and reproducible datasets.3.3. Clinical pathology
All clinical examinations in vivo as laid out in the regulatory
guidelines are feasible, established and reproducible in the marmo-
set. Once the marmoset is gently restrained, it is relatively easy for
experienced staff to take blood samples from the animals or to give
injections. However, the marmoset is too small to allow a large
number of samples to be taken from the same individual for phar-
macokinetic/toxicokinetic or clinical pathology studies. Blood sam-
ples are usually taken from the femoral vein, although the tail vein
can be used for very small toxicokinetic samples. Typically only
15% of the circulating blood volume can be removed within onedern housing facility.
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for a small sample size, similar to that for rodents (Smith et al., 2001;
Zuhlke and Weinbauer, 2003), consequently the marmosets’ small
size does not pose a problem if analyticalmethodologies are already
in place for rodents. Furthermore, the volume of blood required for
pharmacokinetic/toxicokinetic analysis is nowsigniﬁcantly reduced
with the development of ‘‘dried spot blood detection’’ (in some cir-
cumstances down to 30 ll) (Pastori et al., 2010).
The small size of marmosets allows for the collection of urine
using metabolism cages similar to those used for rodents, eliminat-
ing additional difﬁculties associated with the use of larger non-hu-
man primates.
Examination of the eye may be performed with or without
sedation and abnormalities are few with only the anticipated rou-
tine ﬁnding of hyaloid artery remnants in young animals. Screen-
ing compounds for ototoxicity can be performed in sedated
marmosets using the Brainstem Auditory Evoked Response to
monitor hearing loss (e.g. loop diuretics and aminoglycoside anti-
biotics; (Kuzel et al., 1990). Screening potential effects on the car-
diovascular system is an important component of both safety
pharmacology and repeat dose toxicology studies (ICH-Topic-S7A,
2000; ICH-Topic-S7B, 2005; ICH-Topic-M3(R2), 2009). These can
be determined in restrained or sedated marmosets, as in other spe-
cies, but more informative data can be obtained by remote telem-
etry (Schnell and Wood, 1995) which can also monitor motor
activity and body temperature.
Themarmoset is a well-established laboratory species andmany
reviews of pathological changes have been reported as long ago as
the early 1980s with database collection and marmoset pathology
experience continuingwithin a number of establishments. Themar-
moset has its own range of background pathology and, as with any
species, experience is needed in the interpretation of any lesions
found during the course of a toxicology study (Broadmeadow,
2005; Zuhlke and Weinbauer, 2003; Smith et al., 2001).3.4. Dosing
The proposed dosing route in humans determines the dosing
route in the test species and oral, intravenous, intramuscular, sub-
cutaneous, intranasal, intradermal and intraperitoneal are all feasi-
ble in the marmoset. Oral gavage is the most common method of
dosing by way of a rubber catheter. Intravenous dosing is com-
monly performed using the saphenous vein (although some labo-
ratories have successfully employed the cephalic vein). With
experienced technicians, daily intravenous dosing can be per-
formed relatively easily as well as continuous intravenous infusion
(Ruiz de Elvira and Abbott, 1986) and repeated intravenous dosing,
the latter using subcutaneously implanted vascular access ports
(Smith et al., 2001; Zuhlke and Weinbauer, 2003). Intramuscular
injections are usually given in the thigh muscle while subcutane-Table 2
Marmoset use by category in each EU member state for 2005.
Research area New World
EU membe
DE
Biological studies of a fundamental nature 48
Research, development and quality control of products and devices
for human medicine, dentistry and veterinary medicine
22
Toxicological and other safety evaluations 30
Diagnosis of disease
Education and training
Other
* New World monkeys are predominantly marmosets, with a small number of tam
DE = Deutschland, Germany; ES = Spain; FR = France; IT = Italy; NL = Netherlands; SE = Swous injections are made into the upper back or abdomen in combi-
nation with lightweight backpack systems (Smith et al., 2001;
Zuhlke andWeinbauer, 2003). Dietary administration of non-palat-
able products and inhalation are the only dosing methods that
present challenges. For inhalation studies it is possible to provide
masks for the marmoset in a similar fashion to those used for ma-
caques; however, their small size makes this more difﬁcult. A one
month repeated inhalation study has been described using whole
body exposure where the animals were exposed for 6 h per day
to a vapor (Kurata et al., 1997).4. The marmoset in nonclinical development
The marmoset has been used successfully by a number of phar-
maceutical and biotechnology companies to support clinical trials
and for product registration with the United States (US) Food and
Drug Administration (FDA) and the European Medicines Agency
(EMA) (Zuhlke and Weinbauer, 2003; Smith et al., 2001).
The European Union distinguishes six nonclinical categories
where experiments using marmosets may be conducted (Commis-
ion of the European Communities, 2007) as follows:
(1) Biological studies of a fundamental nature
(2) Research, development and quality control of products and
devices for human medicine, dentistry and for veterinary
medicine
(3) Toxicological and other safety evaluations
(4) Diagnosis of disease
(5) Education and training
(6) Other
The distribution of testing according to these categories is out-
lined in Table 2; (Commision of the European Communities, 2007).
The ability of the marmoset to be utilized in fundamental biol-
ogy, pharmacology (pharmacodynamics and pharmacokinetics)
and toxicology studies allows for a strong interconnected relation-
ship between these disciplines, leading to a reduced number of ani-
mals used with a more complete data set at a lower cost (e.g. there
is no need to repeat dose ranging studies, there are less pharmaco-
kinetic/toxicokinetic animals required, less material is required
and development time is reduced).
4.1. Fundamental biology
Marmosets are used widely in the ﬁelds of neural and cognitive
sciences, immunology, infectious disease, reproductive biology and
stem cell research due to their close genetic, physiological and
metabolic similarity to humans (Mansﬁeld et al., 2004). These
activities are centered on understanding fundamental elements
of human biology as well as the pathogenesis of disease syndromesmonkeys* (% of total number for each EU Member State)
r states
ES FR IT NL SE UK
100 6 53 26 18
36 47 46 14
39 28 100 52
2
1
18 13
arins included (SCHER, 2009; Commision of the European Communities, 2007).
eden; UK = United Kingdom.
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tial new medicines.
Recently, several international activities have been imple-
mented to further support the use of the marmoset in nonclinical
development of pharmaceuticals including biotechnology derived
products, gene therapies and vaccines. These include the following:
the signiﬁcant progress in the marmoset genome sequencing
(Mansﬁeld et al., 2004; http://ucscbrowse, 2010), the successful
creation of a marmoset speciﬁc DNA microarray (Datson et al.,
2007, 2009), the public availability of a large collection (3215) of
express sequence tags (ESTs;) of marmoset origin [GenBank:
EF214838 –EF215447, EH380242 – EH382846] (http://www.bio-
medcentral.com/content/supplementary/1471-2164-8-190-S2.xls,
2007) and the creation of transgenic marmosets (Cyranoski, 2009;
Sasaki et al., 2009).4.2. Pharmacodynamics
Marmosets are key pharmacodynamic models in the ﬁelds of
neuroscience, immunology, and infectious disease and also serve
as useful models in other disease areas (Table 3).4.2.1. Neuroscience
Marmosets are widely used models for a number of neurologi-
cal disorders including multiple sclerosis, Parkinson’s disease and
Huntington’s disease (Mansﬁeld et al., 2004) as well as for studies
on normal neurophysiology (Brysch et al., 1990; Hornung et al.,
1990; Guldin et al., 1993; Peretta, 2009).
Multiple sclerosis is a chronic progressive autoimmune disease
of the brain and spinal cord (Rumrill, 2009). The experimental
autoimmune encephalomyelitis (EAE) model in marmosets repre-
sents a chronic relapsing multiple sclerosis (Genain and Hauser,
1997; t Hart et al., 2000; Merkler et al., 2006) whereas the EAE
model, in rodents and in rhesus monkeys, is more reminiscent of
acute disseminated encephalomyelitis. Several nonclinical studies
have been successfully conducted in the EAE marmoset model
using in vivo magnetic resonance imaging (MRI), visual evokeTable 3
Examples of marmoset use in pharmacodynamic studies.
Field Disease/model
Neuroscience Multiple sclerosis
Parkinson’s
Huntington’s
Stroke
Alzheimer’s
Absence epilepsy
Aging
Spinal injury
Immunology Thymic epithelium
Interleukin 2 and 4
Amyloid A (AA) amyloidosis
Induced thrombocytopenia purpurea
Infectious disease Hepatitis
Eastern equine encephalitis
Severe acute respiratory syndrome
Acute oncogenesis
Viral persistence
HIV
Measles pathogenesis
Anthrax
Smallpox virus infection
Viral hemorrhagic fevers
Other Reproductive biology and immuno-contraception
Bone disease
Human physiology
Behavioralpotentials and neuropathology as measures of efﬁcacy (Boretius
et al., 2006; Diem et al., 2008; t Hart andMassacesi, 2009). New po-
tential therapeutic antibodies against human cluster of differenti-
ation (CD) 40 or the shared interleukin-12p40 (IL-12p40) subunit
of interleukins 12 and 23 have been successfully tested in the
EAE marmoset model (Boon et al., 2001; t Hart et al., 2005).
Parkinson’s disease (PD) is a neurodegenerative disease charac-
terized by insufﬁcient production of dopamine from the substantia
nigra area of the brain which leads to signiﬁcant impairment of
movement (Dawson and Dawson, 2002). The marmoset is a recog-
nized model of Parkinson’s disease (Owen et al., 1997) using selec-
tive neurotoxins to destroy the dopamine neurons. The toxins most
commonly used are 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and 6-hydroxydopamine (6-OHDA). More recently, trans-
genic models of the disorder have been developed in marmosets
leading to over-expression of proteins such as a-synuclein using
viral vectors (Kirik et al., 2003; Eslamboli et al., 2007). The exper-
imental use of marmosets is an important intermediary step be-
tween rodent studies and controlled clinical trials when the
phylogenetic similarity to humans is pivotal for assessing and opti-
mizing the efﬁcacy of candidate therapies. However, the marmoset
is not the most suitable non-human primate species to use when
speciﬁc behavioral tests are required (e.g. cognitive testing, tremor
rating) (Eslamboli, 2005).
Huntington’s disease (HD) is a fatal genetic neurodegenerative
disorder with most animal models falling into two broad catego-
ries, non-genetic (e.g. quinolinic acid; QA) and transgenic. Histori-
cally, the former have dominated the ﬁeld of HD research
(Ramaswamy et al., 2007). The unilateral QA putamen lesion in
the marmoset provides a useful and recognized tool for the inves-
tigation of potential treatments (Kendall et al., 1998), however this
model does not replicate the pathology or the symptoms of HD but
rather develops a consistently reproducible lesion with motor
impairments (Kendall et al., 1998, 2000a,b). Recently the marmo-
set huntingtin (Htt) gene has been isolated and identiﬁed, resulting
in the potential to prepare a transgenic HD marmoset model, that
could provide further information on the underlying pathology and
the ability to test therapeutic candidates and gene therapies (Hoh-
joh et al., 2009; Ramaswamy et al., 2007).
4.2.2. Immunology
For the development of IMPs it is of critical importance that po-
tential effects on the immune system (either intended pharmaco-
dynamic or resultant toxicological effects) are investigated in
appropriate models. Non-human primates are typically considered
superior to other models to investigate immunological, pharmaco-
dynamic and potential immune toxic effects on IMPs (Weatherall,
2006).
The marmoset is a key species for several reasons.
 The marmoset represents a unique species for the study of T
and B cell-mediated diseases, because they are born as naturally
occurring bone marrow chimeras (Niblack et al., 1977).
 A large variety of surface receptors on lymphocytes and other
blood cells have been found to cross-react with monoclonal
antibodies against the corresponding human epitopes,
indicating a high degree of similarity between these species
(Barton et al., 1984; Neubert et al., 1996; Riecke et al., 2000;
Kireta et al., 2005; Kametani et al., 2009).
Several studies have been performed resulting in the generation
of a data bank from more than 400 animals, the largest data bank
available for surface receptors (Neubert et al., 1993). However, in
bothmarmosets and humans, somequalitative and quantitative dif-
ferences exist with respect to surfacemarkers on lymphocytes rele-
vant for studies on immunotoxicity: the marmoset lacks natural
Table 4
Summary of marmoset CYP3A characteristics.
CYP3A characteristics
CYP3A21 is the dominant hepatic CYP3A protein in marmosets
The sequence similarity between human CYP3A4 and CYP3A21 in marmoset across the ﬁrst 7.5 kb of the cloned CYP3A21 promoter is 88%.
The marmoset CYP3A21 gene is clustered with the human CYP3A genes, while rodent CYP3A genes form several separate clusters (McArthur et al., 2003; Nelson et al.,
2004; Williams et al., 2004).
The marmoset CYP3A21 cDNA exhibits high similarity to human CYP3A genes (Williams et al., 2004).
The enzymatic activities of CYP3A21 are similar to those of CYP3A4 (Koehler et al., 2006).
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versely cytotoxic killer effector CD4+ cells (CD4+CD56+) found in
marmosets are not found in humans (Neubert et al., 1993).
4.2.3. Infectious disease
Marmosets have been used extensively in infectious disease re-
search due, in large part, to their unique sensitivity to a number of
viruses, bacteria and parasites responsible for human infectious
disease (Mansﬁeld et al., 2004). Furthermore, in an era where biot-
errorism has become a reality, there is an increased demand for
non-human primate models and regulatory authorities have estab-
lished new guidelines for testing vaccines and therapeutics for
pathogens that governments have determined are potential biolog-
ical weapons.
4.3. Pharmacokinetics
The marmoset is also used to investigate the absorption, distri-
bution, metabolism and excretion of new IMPs. In addition, tech-
niques that are not practical in larger non-human primates such
as whole-body autoradiography can be performed in the marmoset
(Broadmeadow, 2005). Furthermore, the marmoset represents a
key model for IMPs that are substrates of cytochrome P450
(CYP450) such as CYP1A2, CYP3A4 and for investigating glucuron-
idation in vitro.
4.3.1. CYP1A2
CYP1A2 is constitutively expressed at a high level in the human
liver and plays an important role in the mutagenic activation of
heterocyclic amines (Butler et al., 1989; Shimada et al., 1994).
CYP1A2 is also constitutively expressed in the liver of marmosets
(Edwards et al., 1994; Bullock et al., 1995) but not in cynomolgus
monkeys. Furthermore, the marmoset and human CYP1A2 respond
to similar inducers, and appear to be under the same or similar
control mechanisms (Sakuma et al., 1997).
4.3.2. CYP3A4
CYP3A4 constitutes the largest fraction of human hepatic
CYP450 and is involved in the metabolism of 45–60% of medicines
currently in use (Koehler et al., 2006). This broad substrate
speciﬁcity represents the basis for many clinically relevant ‘‘medi-
cine-medicine’’ interactions and the marmoset is a key model for
studying these metabolic interactions as there is a strong similarity
between marmoset and human genes, proteins and their functions
(McArthur et al., 2003; Nelson et al., 2004; Williams et al., 2004;
Koehler et al., 2006) (Table 4).
4.3.3. Uridine diphosphate glucuronosyltransferases
Uridine diphosphate glucuronosyltransferases (UGT) are a large
family of membrane bound enzymes responsible for the detoxiﬁca-
tion of a wide range of xenobiotics and endogenous compounds.
The large number of products glucuronidated, whether directly
or following the Phase I step, necessitates a thorough understand-
ing of glucuronidation for efﬁcient pharmaceutical development
(Dutton, 1980). Typically, rodents are used as the primary animal
model and the dog commonly used as the second animal modelfor pharmacokinetic studies. However a wide range of products
are more extensively glucuronidated by dog liver microsomes
when compared with human hepatic microsomes (Soars et al.,
2001). Furthermore, qualitative differences in glucurondation are
observed between dogs and humans with extrahepatic glucuroni-
dation being markedly reduced in dogs (Soars et al., 2001). By con-
trast, there are quantitative and qualitative similarities between
human and marmoset glucuronidation in vitro and as such the
marmoset is a useful model especially when the rate and pathway
of glucuronidation of a medicine are known to differ signiﬁcantly
between rodents, dogs and humans (Soars et al., 2001). The signif-
icant extrahepatic (e.g. kidney) glucuronidation observed in mar-
mosets in comparison with other animals merits its use for
preclinical pharmacokinetic and safety evaluation studies. Never-
theless, further work should also be performed to conﬁrm that
observations in different species in vitro accurately represent the
situation in vivo (Soars et al., 2001).
4.4. Toxicology
Toxicological and other safety evaluations, represent the largest
use of marmosets in nonclinical development with typical use
being for acute, sub-acute, chronic and toxicokinetic studies (Com-
mision of the European Communities, 2007). Interestingly, long
term studies of up to 6.5–7 years duration have also been reported
(Smith et al., 2001) (Table 5).
The marmoset can be used for pharmacology as well as for tox-
icology studies. In addition, there are well-established classes of
compounds where the marmoset may well offer an alternative spe-
cies to the dog that shows hypersensitivity or idiosyncrasy (Smith
et al., 2001; Gaudy et al., 1987) (Table 6).
4.4.1. Teratology, reproductive and related studies
Marmosets represent a useful model to investigate the terato-
logic potential of pharmaceuticals and to investigate aspects of
reproductive physiology and immune-contraception due to their
early sexual maturity, high reproduction efﬁciency and similarities
in placentation to humans (Mansﬁeld et al., 2004) (Table 7).
By contrast, there are several aspects of the reproductive pro-
cess in marmosets that exhibit discrepancies to those described
for humans (Cline, 2007; Luetjens et al., 2005; Zuhlke and Wein-
bauer, 2003). The differences for females include multi-ovulation,
postpartum conception, the lack of external signs of menstruation
and for males include alterations or even absence of genes known
to be essential for reproductive development. The duration of the
menstrual cycle in marmosets varies, on average, from 16 to
28 days and unlike women, the luteal phase is comparatively long
at the expense of the follicular phase with 1 and 4 eggs ovulated. A
mid-phase follicle stimulating hormone (FSH) peak and the pres-
ence of multiple dominant follicles in marmosets represents an-
other difference to humans (Zuhlke and Weinbauer, 2003).
For juvenile toxicology studies, useful background data has
been generated in the marmoset over the years examining differ-
ences in clinical pathology endpoints and organ weights between
young and adult marmosets (Wadsworth et al., 1981; Davy et al.,
1984).
Table 6
Compound classes where marmosets may be more suitable as a model than dogs.
Class of compounds where marmosets may be a more suitable
model than dogs
Vomiting with morphine compounds
Atrio-ventricular block with calcium antagonists
Reﬂex tachycardia with anti-hypertensives
Allergic reactions with vehicles such as cremophor
Table 5
Examples of marketed products where marmosets were used in their development.
Therapeutic class Product name Toxicity study:
route/duration
Notes References
Anti-hypertensive Cilazapril (Inhibace) Oral: 2, 4 and
26 weeks; Intra-
venous: 2 weeks
Angiotensin converting enzyme (ACE) inhibitor for
the treatment of hypertension and congestive heart
failure
Hoffmann-LaRoche (2008)
Anti-retroviral Saquinavir mesylate
(Invirase)
Oral: 2, 4, 26 weeks
Intra-venous: 2 and
4 weeks
Proteinase inhibitor for human, immunodeﬁciency
virus (HIV)
Hoffmann-LaRoche (2009)
Anti-viral Oseltamivir phosphate
(Tamiﬂu)
Oral: 1, 4 and 39 weeks Neuraminidase inhibitor for seasonal ﬂu and more
recently swine ﬂu
Hoffmann-LaRoche (2009)
Chemotherapeutic Mitomycin C
(Mutamycin)
Oral: 39 weeks Antibiotic isolated from the broth of Streptomyces
caespitosus which has antitumor activities
Matsumoto et al. (1987)
Lipid lowering agent Fibrates (e.g.
ciproﬁbrate and
cloﬁbrate)
Oral: several studies up
to 7 years
Fibrates are hypolipidaemic agents which, in
chronic studies in rats or mice, have produced
tumors or pre-neoplastic changes not predictable
for humans. Cloﬁbrate and ciproﬁbrate toxicity
studies up to 7 years duration conducted by two
laboratories have shown that the marmoset is
predictive for humans and in the marmoset studies,
unlike rodents, there is no induction of liver tumors
Eason et al. (1988), Spencer
et al. (1989), Smith et al.
(2001), Reddy et al. (1983),
Makowska et al. (1992),
Graham et al. (1994)
Non steroidal anti-
inﬂammatory
Indomethacin Oral: 4 weeks Non-steroidal anti-inﬂammatory to reduce fever,
pain stiffness and swelling. It inhibits prostaglandin
release
Oberto et al. (1990)
Parkinson’s disease Ropinirole Oral-safety studies Ropinirole at microgram/kg doses produced
signiﬁcant decreases in the number of postures and
signiﬁcant increases in the time spent at the cage
front in the ‘‘human threat’’ test. In rodents the
effects were seen at mg/kg
Eden et al. (1991)
Psychotic disorders
including schizophrenia
Clozapine Oral, intramuscular-
safety studies
Clozapine over a wide dose range, unlike other
antipsychotics, increased the motivational state of
the marmoset suggesting a unique clinical proﬁle
Cilia et al. (2001)
Varies Thalidomide The marmoset has been used to comprehensively
investigate the mechanism of thalidomide
teratogenesis
Heger et al. (1994); Neubert
et al. (1996)
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Once the scientiﬁc rationale has been carefully considered and its
use as the non-rodent species justiﬁed, there are considerable
advantages in using the marmoset as a model in pharmaceuticalTable 7
Examples of marmoset use in teratology and reproductive studies.
Marmoset use in teratology and reproductive studies
Higher non-human primates, such as the cynomolgus and rhesus monkeys, have gen
However, multigenerational studies are feasible in the marmoset, which has a com
To investigate the mechanism of thalidomide teratogenesis: metabolites of thalidomid
cell to cell and cell to extracellular matrix interactions within the developing limb
To examine the effect of luteinizing hormone and follicular stimulating hormone on gr
Hillier et al., 1997)
To deﬁne the mechanisms of estradiol inactivation, in vitro fertilization, embryo transf
1997, 1998, 2003a; Luetjens and Wesselmann, 2008)
To determine whether infant feeding with soya formula milk, which contains high le
developing testis and reproductive system of the male. An initial study found that
longer term follow-up analysis of these animals indicated that infant feeding with s
does alter testis size and cell composition. The authors concluded that similar chang
2002; Tan et al., 2006)product development. These range from reduced material require-
ment due to their small size (up to15 fold less), a predicted acceler-
ation of development (up to 18 months faster), an earlier
assessment of product candidates in the adult due to their early sex-
ual maturation and reduced numbers of animals required due to
their ability to be used in bothpharmacology and toxicology studies.
These factors, alongside a better understanding of their optimal
nutrient and welfare requirements over recent years, facilitate the
generation of a more cohesive and robust dataset. With the growth
of biotechnology-derived products and gene therapies, the use of
non-human primates has, by necessity, also increased since these
are often the only relevant species that provide an adequate safety
assessment. Nevertheless, there is a growingpublic call forminimiz-
ing their use now and in the future. Utilizing, the more primitive
marmoset species may provide the optimal compromise.eration times of about 5 years, making multigenerational studies impractical.
paratively short generation time (14–18 months) (Marshall et al., 2003b)
e may cause the down-regulation of surface adhesion receptors thereby altering
bud (Heger et al., 1988, 1994; Klug et al., 1994; Neubert et al., 1996)
anulosa cell development and steroidogenesis (Barrett, 2007; Millar et al., 2000;
er and parthenogenesis (Husen et al., 2001; Summers et al., 1987; Marshall et al.,
vels of plant estrogens, poses any immediate or longer-term health risk to the
testosterone levels were suppressed in animals fed with soya formula milk. A
oya formula milk had no gross reproductive effects in male marmosets, but that it
es are likely to occur in adult men fed soya formula milk as infants (Sharpe et al.,
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